MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A novel mobile application for monitoring the response to botulinum toxin in patients with Cervical Dystonia.

M. Bradley, C. Edwards, R. Borton, A. Ross, F. Molloy (Dublin, Ireland)

Meeting: 2023 International Congress

Abstract Number: 768

Keywords: Botulinum toxin: Clinical applications: dystonia

Category: Dystonia: Clinical Trials and Therapy

Objective: A pilot study to determine the acceptability of a novel DystoniaDiary application in patients with Cervical Dystonia (CD) attending a specialist clinic.

Background: The mainstay of treatment for CD is botulinum toxin injections every 3-4 months. Clinical evaluation of response is dependent on the patient’s recall of how well symptoms responded to the previous injection.A mobile health application could assist in monitoring both benefits and side effects to assist with selection of muscle and toxin dose at the next visit.

Method: A mobile app (DystoniaDiary) was developed for the collection of patient-reported symptoms of CD based on questions derived from the validated Cervical Dystonia Impact Profile (CDIP 58 ) questionnaire. Patients gave informed consent. These patients attend a specialist botulinum toxin clinic every 3-4 months and are reviewed by the same neurologist. All injections are administered under EMG guidance. The DystoniaDiary was installed as an application (‘’app”) on the patient’s smartphone/tablet device. Patients were prompted every 3 days to record the level of symptom control. Patient opinion and experience were assessed by questionnaire at weeks 4 and 12.The data collected were reviewed to assess its usefulness as a patient-clinician interface for evaluation of post-injection outcomes.

Results: 34 patients used the DystoniaDiary mobile app on at least one occasion. 25 patients (74%) recorded data for ≥12 weeks and 21 patients (62%) for ≥16 weeks. Median time between first and last data input was 140 days with a median of 13 recordings/patient. User experience questionnaires at Weeks 4 and 12 (20 respondents) indicated that the majority of respondents found the Dystonia Diary app easy to use, would recommend it to others (19/20) and wished to continue using it (16/20). A smaller proportion indicated that the DystoniaDiary gave a greater sense of control in managing their CD (13/20). Response to treatment was apparent in the symptom control scores of some patients whereas the severity of other patients’ symptoms did not appear to change during treatment.

Conclusion: This pilot study demonstrates that there is a potential for a positive impact from mobile health technology in the management of CD. Further long term studies including real time feedback are needed to identify best practices and evaluate the sustainability of technology on the treatment of CD.

To cite this abstract in AMA style:

M. Bradley, C. Edwards, R. Borton, A. Ross, F. Molloy. A novel mobile application for monitoring the response to botulinum toxin in patients with Cervical Dystonia. [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/a-novel-mobile-application-for-monitoring-the-response-to-botulinum-toxin-in-patients-with-cervical-dystonia/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-novel-mobile-application-for-monitoring-the-response-to-botulinum-toxin-in-patients-with-cervical-dystonia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley